



Inside Cancer Genomics: From Structure to Therapy

Guest Editor:

Dr. Vincenza Barresi

Department of Biomedical and
Biotechnological Sciences,
Section of Medical Biochemistry,
University of Catania, 95123
Catania, Italy

Deadline for manuscript
submissions:

closed (15 May 2022)

Message from the Guest Editor

Dear Colleagues,

Cancer initiation, growth, and progression are sustained by point mutations, focal genomic errors, and, last but not least, broad chromosomal copy number alterations. In recent years, our extensive knowledge of DNA mutations in cancer genomes has inspired a vast range of targeted therapies. These mutations can hit protein-coding genes and noncoding regions and, via heterogeneous mechanisms, are crucial in tumorigenesis. However, it is significant that almost all solid tumors are characterized by a high percentage of aneuploidy (50–80% depending on the specific tumor), and its impact on cancer driver genes and gene networks is poorly known. The context seems to include both single mutation–single pathogenic gene and single alteration–multiple candidate pathogenic genes affecting DNA and RNA molecules.

This Special Issue will focus on the role and contribution of focal and broad alterations in cancer genomics in order to ameliorate cancer diagnosis and prognosis and to design new precision therapies.

Dr. Vincenza Barresi
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)